γδ T-PD-1 Ab cells
Phase 1Biologic
γδ T-PD-1 Ab cells is one of 72 biologic programs targeting Advanced Solid Tumors. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Beyfortus
BeiGenePhase 2
Taxotere
AAvyxa
Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Braftovi
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Recruiting·—·Phase 1·NCT06404281·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for γδ T-PD-1 Ab cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Medical University